These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 29289555

  • 1. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK, Bihani T.
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [Abstract] [Full Text] [Related]

  • 2. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
    Lu Y, Liu W.
    J Med Chem; 2020 Dec 24; 63(24):15094-15114. PubMed ID: 33138369
    [Abstract] [Full Text] [Related]

  • 3. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK, Castiglione-Gertsch M.
    Minerva Ginecol; 2009 Dec 24; 61(6):517-39. PubMed ID: 19942839
    [Abstract] [Full Text] [Related]

  • 4. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
    Bhatia N, Hazra S, Thareja S.
    Eur J Med Chem; 2023 Aug 05; 256():115422. PubMed ID: 37163948
    [Abstract] [Full Text] [Related]

  • 5. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
    Hernando C, Ortega-Morillo B, Tapia M, Moragón S, Martínez MT, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo JM.
    Int J Mol Sci; 2021 Jul 22; 22(15):. PubMed ID: 34360578
    [Abstract] [Full Text] [Related]

  • 6. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
    Wang Y, Tang SC.
    Cancer Metastasis Rev; 2022 Dec 22; 41(4):975-990. PubMed ID: 36229710
    [Abstract] [Full Text] [Related]

  • 7. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.
    Li CL, Moi SH, Lin HS, Hou MF, Chen FM, Shih SL, Kan JY, Kao CN, Wu YC, Kao LC, Chen YH, Lee YC, Chiang CP.
    Int J Mol Sci; 2022 Sep 11; 23(18):. PubMed ID: 36142451
    [Abstract] [Full Text] [Related]

  • 8. Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
    Gombos A.
    Curr Opin Oncol; 2019 Sep 11; 31(5):424-429. PubMed ID: 31335829
    [Abstract] [Full Text] [Related]

  • 9. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021-December 2023).
    Scott JS, Klinowska TCM.
    Expert Opin Ther Pat; 2024 May 11; 34(5):333-350. PubMed ID: 38836316
    [Abstract] [Full Text] [Related]

  • 10. Accelerating drug development in breast cancer: New frontiers for ER inhibition.
    Ferraro E, Walsh EM, Tao JJ, Chandarlapaty S, Jhaveri K.
    Cancer Treat Rev; 2022 Sep 11; 109():102432. PubMed ID: 35839531
    [Abstract] [Full Text] [Related]

  • 11. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
    McDonnell DP, Wardell SE.
    Curr Opin Pharmacol; 2010 Dec 11; 10(6):620-8. PubMed ID: 20926342
    [Abstract] [Full Text] [Related]

  • 12. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Rizzo P, Marino A, D'Amico M, Sponziello F, Mazzoni E, Cinefra M, Fazio N, Maiello E, Silvestris N, Colucci G, Cinieri S.
    Cancer Treat Rev; 2010 Nov 11; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [Abstract] [Full Text] [Related]

  • 13. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS, Jordan VC.
    Mutat Res; 2005 Dec 11; 591(1-2):247-63. PubMed ID: 16083919
    [Abstract] [Full Text] [Related]

  • 14. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
    Xiong R, Zhao J, Gutgesell LM, Wang Y, Lee S, Karumudi B, Zhao H, Lu Y, Tonetti DA, Thatcher GR.
    J Med Chem; 2017 Feb 23; 60(4):1325-1342. PubMed ID: 28117994
    [Abstract] [Full Text] [Related]

  • 15. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
    Keenan JC, Medford AJ, Dai CS, Wander SA, Spring LM, Bardia A.
    Expert Rev Anticancer Ther; 2024 Jun 23; 24(6):397-405. PubMed ID: 38642015
    [Abstract] [Full Text] [Related]

  • 16. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
    Haines CN, Wardell SE, McDonnell DP.
    Essays Biochem; 2021 Dec 17; 65(6):985-1001. PubMed ID: 34328178
    [Abstract] [Full Text] [Related]

  • 17. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models.
    Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, Purandare DM, Hattersley G, Garner F.
    Clin Cancer Res; 2017 Aug 15; 23(16):4793-4804. PubMed ID: 28473534
    [Abstract] [Full Text] [Related]

  • 18. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
    Scott JS, Barlaam B.
    Expert Opin Ther Pat; 2022 Feb 15; 32(2):131-151. PubMed ID: 34763600
    [Abstract] [Full Text] [Related]

  • 19. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
    Sengupta S, Jordan VC.
    Adv Exp Med Biol; 2008 Feb 15; 630():206-19. PubMed ID: 18637493
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.
    Das A, Lavanya KJ, Nandini, Kaur K, Jaitak V.
    Curr Med Chem; 2023 Feb 15; 30(29):3287-3314. PubMed ID: 36201273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.